Source: ERJ Open Res, 5 (4) 00092-2019; 10.1183/23120541.00092-2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Christian Taube, Peter Bramlage, Annette Hofer, Dörte Anderson. Prevalence of oral corticosteroid use in the German severe asthma population. ERJ Open Res, 5 (4) 00092-2019; 10.1183/23120541.00092-2019

Member's Comments

No comment yet.

Related content which might interest you: Oral corticosteroid use in Swedish and Finnish severe asthma patients Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019 Effect of maintenance oral corticosteroids on risk factors for frequent exacerbations in a severe adult asthma population Source: Virtual Congress 2020 – Severe asthma phenotypes and outcomes Year: 2020 Predictors of adherence to inhaled corticosteroids in children with asthma and their parents in a multi-ethnic population Source: Annual Congress 2007 - Education, communication and quality of life in childhood asthma Year: 2007 Oral corticosteroid prescription in asthma: Swiss situation Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Prevalence of the use of oral corticosteroids in asthma – a 3-year analysis in Germany Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019 Genome-wide association study of asthma symptoms despite inhaled corticosteroids use in Dutch children. Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Oral corticosteroids-related comorbidities in severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Oral corticosteroids in the treatment of exacerbation of severe asthma Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020 Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006–2016 Source: Eur Respir J, 53 (4) 1802130; 10.1183/13993003.02130-2018 Year: 2019 Study to evaluate clinical burden related with oral corticosteroids treatment of severe asthma in Spain (LEVANTE) Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Antibiotics use for asthma exacerbation in Japanese geriatric patients Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019 Combination asthma medication and healthcare use in severe or difficult-to-treat asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Efficacy of montelukast in Indian patients having chronic persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003 Is there a problem with oral corticosteroid use in asthma? Source: Virtual Congress 2020 – Airway diseases Year: 2020 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Measures of adherence in patients with severe asthma prescribed systemic steroids in the U-BIOPRED cohort Source: International Congress 2018 – Clinical markers of asthma Year: 2018 Chronic oral corticosteroids use and persistent eosinophilia in severe asthma. The Belgian Severe Asthma Registry. Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 Pattern of asthma control and inhaled corticosteroid (ICS) use in an Australian asthma population Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme Source: Eur Respir J, 55 (6) 1902345; 10.1183/13993003.02345-2019 Year: 2020